Risk of Uncomplicated Peptic Ulcer in the General Population

July 14, 2014 updated by: AstraZeneca

The analyses are conducted in a previous population-based cohort study using The Health Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses are:

To estimate the relative risk of uncomplicated symptomatic peptic ulcer (UPU) associated with use of low dose aspirin (ASA) and other anti-inflammatory drugs (NSAIDs, steroids) in the general population To estimate the dose-response and duration-response associated with use of these drugs To estimate the relative risk of UPU associated with naive/non-naive use of low dose ASA in the general population To evaluate the effect of proton pump inhibitors (PPI) (alone or in combination with anti-inflammatory drugs) on the occurrence of UPU in the general population To investigate the management of low dose ASA/oral antiplatelets after UPU

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Risk of uncomplicated peptic ulcer in the general population

Study Type

Observational

Enrollment (Actual)

4000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Madrid, Spain
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 84 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study is conducted using The Health Improvement Network database in the UK. Patients aged 40-84 years between January 1997 and December 2005 with a registration status of permanent or deceased, who were enrolled for at least 2 years with a GP and had 1 year of electronic prescription history. Patients with a code for cancer, peptic ulcer (both uncomplicated and complicated), upper GI bleeding, oesophageal varices, Mallory-Weiss disease, alcohol abuse, liver disease, or coagulopathies before beginning date were excluded from the source population. All patients in the study population were followed up until the end of the study period (December 2005), or until they reached the age of 85, died, met any of the exclusion criteria (including receiving a diagnosis of complicated peptic ulcer disease), or received a diagnosis of uncomplicated peptic ulcer disease.Patient records were manually reviewed to validate cases.

Description

Inclusion Criteria:

- Patients aged 40-84 years in 1997-2005 ( see study population description)

Exclusion Criteria:

- Patients aged below age 40 and 85 years and above ( see study population description)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cases
Patients with symptomatic peptic ulcer (UPU)
Drug: Risk of symptomatic peptic ulcer
Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
Control group
Control group without symptomatic peptic ulcer (UPU).
Drug: Risk of symptomatic peptic ulcer
Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relative risk (ratio) of uncomplicated peptic ulcer (UPU) associated with low dose ASA, other antiinflammatory drugs and other common drugs for chronic diseases(paracetamol, SSRI, tricyclic antidepressants, anticoagulants, acid suppressing drugs)
Time Frame: From Januar 1 1997 till December 31 2005, an expected average of 4 years.
Relative risk (ratio) of UPU associated with current use of the different types of drugs versus non-use.
From Januar 1 1997 till December 31 2005, an expected average of 4 years.
Management of aspirin after uncomplicated peptic ulcer (UPU).
Time Frame: From January 1, 1997 till december 31, 2005, an average of 4 years
From January 1, 1997 till december 31, 2005, an average of 4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2012

Primary Completion (Actual)

May 1, 2013

Study Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

March 18, 2013

First Submitted That Met QC Criteria

June 26, 2013

First Posted (Estimate)

June 28, 2013

Study Record Updates

Last Update Posted (Estimate)

July 15, 2014

Last Update Submitted That Met QC Criteria

July 14, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D5040N00006

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peptic Ulcer [Iowa Type (107680.0010)]

Clinical Trials on Risk of symptomatic peptic ulcer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe